H ematopoietic stem cell transplantation (HSCT) is an important treatment for a variety of malignant and nonmalignant conditions. During the last few decades, there has been significant progress in the procedure and care of patients after transplantation. Annually, there are Ͼ30,000 cases of autologous HSCT and 15,000 cases of allogeneic HSCT performed worldwide (1). Hematopoietic stem cells may be obtained from bone marrow, peripheral blood, or umbilical cord blood. Depending on the source of these stem cells, HSCT is classified as autologous if the cells are taken from an individual patient and stored for reinfusion after high-dose chemotherapy, and it is classified as allogeneic if the stem cells are donated from another individual (who may or may not be related). In the case of allogeneic HSCT, the conditioning regimen before transplantation may be myeloablative, in which supralethal doses of chemotherapy and irradiation are given, leading to significant toxicity and immunosuppression. More recently, nonmyeloablative regimens have been used to minimize the toxicity related to the conditioning regimen and allow for immunologically mediated killing of tumor cells (graft vs. tumor effect) (2-4).
Despite of the advances in HSCT, the procedure remains limited by the high rate of severe complications that are generally related to toxicity of conditioning regimen, immunosuppression, and graftvs.-host disease (GVHD). These complications are commonly associated with critical illness and require admission or transfer to the intensive care unit (ICU). The range of transfer to the ICU is between 11% and 40% of all HSCT recipients (5, 6). More than 60% of these patients require mechanical ventilation, which is associated with very high mortality (6).
There is a wide spectrum of complications seen in critically ill HSCT recipients (Table 1) . These complications usually develop in the first 100 days after HSCT and are associated with a high mortality rate (6). Moreover, severe complications in critically ill HSCT recipients tend to follow a predictable timeline that helps in the diagnostic and therapeutic approaches (Fig. 1 ). This article focuses on the complications in critically ill HSCT recipients, reviewing the risk factors, diagnostic studies, outcomes, and suggested approaches to management.
Pulmonary Complications
Acute respiratory failure is the most common reason for care in the ICU after HSCT (7, 8) . In a recent study of HSCT recipients admitted to the ICU, acute respiratory failure was the reason for transfer in 48% of patients (6). Of patients with acute respiratory failure, 60 -85% require mechanical ventilation (5-23). The prognosis of those patients who develop acute respiratory failure after HSCT, especially those who are intubated, is very poor, with a mortality rate approaching 100%. However, recent studies show an improvement in the outcome of these patients (Table 2 ). In addition to developing acute respiratory failure as a result of many of the complications mentioned in this article, the following pulmonary problems are unique causes of acute respiratory failure after HSCT.
Engraftment Syndrome. Engraftment syndrome develops within 96 hrs of engraftment (neutrophils, Ն500 cells/cm 3 ) (24). The syndrome is reported in 7-35% of HSCT recipients (25-29). Engraftment syndrome is described following autologous HSCT; however, it is also seen in patients following allogeneic transplantation and is characterized by fever, erythematous rash, diarrhea, renal impairment, and diffuse pulmonary infiltrates (noncardiogenic pulmonary edema due to capillary leak) (25, 26, 30) . In the most severe cases, it may lead to profound hemodynamic collapse and multiple organ system failure (MOSF) (24). The syndrome coincides with neutrophil recovery and is postulated to be due to the release of cytokines by these neutrophils (31, 32). The use of granulocyte colonystimulating factor may increase the prevalence of the syndrome (33). Treatment is supportive, some of these patients require mechanical ventilation, and granulocyte colony-stimulating factor should be discontinued. Prompt use of systemic corticosteroids has been shown to decrease the duration and complications related to this syndrome (24, 25, 28). Mortality secondary to engraftment syndrome is around 25% (33).
Diffuse Alveolar Hemorrhage. Diffuse alveolar hemorrhage (DAH) is one of the most important noninfectious pulmonary complications following HSCT, leading to acute respiratory failure. DAH is reported with an average frequency of 5% following HSCT (range, 2-14% in different reports) (34 -39). DAH is slightly more common following autologous rather than allogeneic HSCT (34 -37, 40 -46). Furthermore, DAH is estimated to constitute 40% of all causes of acute respiratory failure admitted to the ICU (20, 39, 47) . In a recent study, 85% of patients with DAH were admitted to the ICU, and 77% of those required mechanical ventilation (48). The main risk factors for DAH are intensive chemotherapy before HSCT, total body irradiation, older age, white blood cell count recovery, and renal insufficiency (41, 42, 49) . Pathogenesis of DAH is injury of the endothelial cells of small blood vessels and thrombotic microangiopathy due to high-dose chemotherapy (39). In addition, there is an element of alveolitis that may be related to acute GVHD (50). Cytokines such as interleukin-12 and tumor necrosis factor-␣ are believed to mediate the pathologic changes seen in DAH (39, 50). These findings correlated with marrow recovery and influx of neutrophils to the lungs (34). DAH usually develops in the first 30 days (mostly in the first 11-19 days); however, it may develop later on following HSCT (39, 42, 48, 51). The syndrome is characterized by progressive dyspnea, cough, fever, and hypoxemia. Hemoptysis is rare. The chest radiograph shows bilateral interstitial and alveolar infiltrates that tend to be perihilar and in lower lobes (38). These radiologic findings may precede by an average of 3 days the clinical presentation (38). High-resolution computerized tomography of the chest shows bilateral ground glass infiltrates (42, 52). Although many of these patients have thrombocytopenia and coagulopathy, there is no correlation between these factors and the development of DAH (42). Bronchoalveolar lavage (BAL) is the best tool to diagnose DAH. The most common finding early in the course of DAH is a progressively bloodier BAL fluid return, and later, the only finding may be hemosiderin-laden macrophages (39, 42). However, the absence of either finding does not exclude the diagnosis of DAH. The following criteria are suggested to define this syndrome: 1) evidence of widespread alveolar injury manifested by multilobar pulmonary infiltrate, symptoms and signs of pneumonia, and abnormal pulmonary physiology with increased alveolar to arterial oxygen gradient and restrictive ventilatory defect; 2) absence of infection that may be associated with similar presentation; and 3) BAL showing progressively bloodier return from three separate subsegmental bronchi or the DAH, diffuse alveolar hemorrhage; IPS, idiopathic pneumonia syndrome; BOOP, bronchiolitis obliterans organizing pneumonia; BO, bronchiolitis obliterans; CMV, cytomegalovirus; RSV, respiratory syncytial virus; HZV, herpes zoster virus; PCP, Pneumocystis carinii pneumonia; GVHD, graft-vs.-host disease; GI, gastrointestinal; VOD, veno-occlusive disease; DMSO, dimethyl sulfoxide; HUS, hemolytic uremic syndrome; CVA, cerebrovascular accident; CNS, central nervous system; TTP, thrombotic thrombocytopenic purpura. ϩϩϩ, common; ϩϩ, less common; ϩ, rare; Ϯ, extremely rare.
presence of Ն20% hemosiderin-laden macrophages or the presence of blood in Ն30% of the alveolar surfaces of lung tissue (39). The treatment of DAH is supportive. Patients are commonly treated by high-dose systemic corticosteroids, although there are no prospective randomized studies to confirm the benefit of this treatment in HSCT recipients. In retrospective studies, high-dose methylprednisolone (125-250 mg every 6 hrs for 4 -5 days and then tapered over 2-4 wks) was associated with a better outcome compared with low-dose (Ͻ30 mg/day) or no corticosteroids groups (34, 39, 48). The prognosis of DAH is poor, with a mortality rate of 72% (range, 64 -100%) (48). Only 15% die due to progressive respiratory failure; however, the most common causes of death are MOSF and sepsis (48). In a recent analysis of patients with DAH, the mortality rate was less (48%), and the prognosis was better in patients with autologous HSCT and early onset of DAH (Ͻ1 month) (48).
Idiopathic Pneumonia Syndrome. Idiopathic pneumonia syndrome (IPS) is a syndrome of diffuse lung injury that develops following HSCT in which an infec- primarily seen in allogeneic HSCT recipients, and the prevalence is reported to be 1.4% (49). The syndrome is believed to be related to GVHD and is characterized histologically by the presence of intraluminal granulation consisting of fibroblasts in the small airways, alveolar ducts, and the alveoli. There is also interstitial infiltration by lymphocytes and macrophages. Bronchiolitis obliterans organizing pneumonia usually develops 1-3 months after HSCT (70 -73). Patients usually present with dyspnea, dry cough, and fever. They are commonly hypoxemic and may develop acute respiratory failure requiring mechanical ventilation. The condition is usually misdiagnosed as pneumonia; however, cultures are negative. Highresolution computerized tomography of the chest shows patchy consolidation with ground glass attenuation (52, 74). The diagnosis is confirmed by surgical lung biopsy. Transbronchial biopsy may provide the diagnosis in a small number of patients (75). Establishing the diagnosis is essential because these patients have a good response to long-term systemic corticosteroid therapy (75). The overall case fatality in patients with bronchiolitis obliterans organizing pneumonia following HSCT is 21% (49, 70 -73). Bronchiolitis obliterans organizing pneumonia is different from bronchiolitis obliterans, which is an inflammatory disease of the small airways that develops later in the course of allogeneic HSCT (76). It leads to progressive obstructive airway disease with no parenchymal involvement (77). Bronchiolitis obliterans gradually worsens over months to years and patients eventually die of respiratory failure. The treatment of bronchiolitis obliterans is difficult, and these patients do not respond well to systemic corticosteroids (78 -81). Chronic therapy with macrolides may slow the progression of this disease (82, 83).
Severe Infections
Severe infections are a major complication following HSCT. They are estimated to be the cause for admission or transfer to the ICU in 23% of patients (6). Furthermore, severe infections are a significant problem in critically ill HSCT recipients, especially those who are on broad-spectrum antibiotics, with indwelling catheters, or who are mechanically ventilated. HSCT recipients are at risk for bacterial and candidal infections; however, they are also prone to a variety of opportunistic infections such as invasive pulmonary aspergillosis (IPA), CMV, and Pneumocystis carinii pneumonia. The main factors that predispose HSCT recipients to these infections are impaired humoral and cellular immunity, neutropenia, breakdown in cutaneous and mucosal barriers, and immunosuppressive therapy.
Bacterial Viral Infections. Viral infections are common following HSCT and may occasionally result in critical illness. These viruses include CMV, herpes zoster virus, respiratory syncytial virus, human herpes simplex virus 6, and adenovirus (88, 89). The most serious complication of these viral infections is pneumonitis with acute respiratory failure; however, they may lead to other organ dysfunctions such as hepatitis, encephalitis, and bone marrow suppression (90). CMV is the most important viral infection following HSCT, and pneumonitis is the most severe manifestation of this infection. The patients at highest risk for CMV infection are those CMV-seronegative recipients receiving hematopoietic stem cells from seropositive donors. Other risk factors include older age, transplantation for hematologic malignancy, total body irradiation, antithymocyte globulins, neutropenia, GVHD, and CMV seroconversion (89, 91-93). Before routine prophylaxis, the prevalence of CMV disease was 20 -35%, with mortality reaching 100% (94, 95). Recently, the prevalence of CMV disease decreased significantly because of two important interventions. The first is routine prophylaxis against CMV using ganciclovir in high-risk patients in the first 100 days following HSCT (95). The second is preemptive treatment of patients with subclinical viremia detected by surveillance pp65 antigenemia or polymerase chain reaction assay (94, 96 -98). Currently, CMV pneumonia in the first 100 days occurs in 6% of patients; however, the prevalence beyond the first 100 days increased from 4% to 15%, with the highest risk for late CMV pneumonia being the presence of chronic GVHD (89). CMV pneumonia usually presents a median of 7 wks after transplantation, with nonproductive cough, dyspnea, fever, and hypoxemia that quickly progresses to acute respiratory failure (89). Highresolution computerized tomography of the chest is the best diagnostic radiologic study and usually shows diffuse interstitial nodules and ground glass infiltrates (99). The diagnosis is established by demonstrating viral inclusion bodies in lung tissue biopsy (91). Other studies that are suggestive of CMV pneumonia are positive CMV culture and positive direct fluorescence assay or polymerase chain reaction on BAL fluid (91). Serum pp65 antigen assay is routinely available, and the test may be the first indication of CMV pneumonia (97). Treatment of CMV pneumonia using ganciclovir and immunoglobulins, especially when started early in the course of the illness, resulted in significant improvement in survival. Uncontrolled trials show survival rates of 50 -70% compared with the historical 0 -15% (53, 100, 101). However, it is important to note that ganciclovir treatment is associated with significant side effects, including neutropenia, nephrotoxicity, seizures, and retinal detachment. Foscarnet is an alternative that may also lead to acute renal failure. Respiratory syncytial virus pneumonia is another severe viral infection following HSCT. It usually develops in the first month following transplantation and has seasonal variation. The infection presents with upper respiratory tract symptoms that progress to lower respiratory symptoms. The diagnosis is made by detecting the virus by nasal wash or BAL fluid culture (102). Once pneumonia develops, mortality is very high and approaches 80% (102, 103). Uncontrolled trials suggest that the combination of aerosolized ribavirin and intravenous immunoglobulins decrease mortality, especially if started before the onset of acute respiratory failure (104, 105). Herpes zoster virus infection following HSCT is rare but may lead to a disseminated disease with pneumonia, hepatitis, skin rash, encephalitis, and disseminated intravascular coagulation (106, 107). High-dose acyclovir is the treatment of choice (108). Human herpes simplex virus 6 is another severe viral infection following HSCT and may cause pneumonitis, marrow suppression, and encephalitis. Treatment is by ganciclovir or foscarnet (89, 91).
Fungal Infections. Fungal infections are increasingly identified in critically ill HSCT recipients. Candida species is the most commonly isolated fungal infection in this patient population. The prevalence of invasive candidal infection is estimated to be 1.3-10%, with mortality reaching 50% (109 -112). Routine prophylaxis against Candida using fluconazole during the neutropenic phase has significantly decreased the prevalence of severe Candida infection in HSCT recipients (112). Candidemia is the most common serious manifestation of this infection; however, other internal organs may be affected, including hepatic and splenic infections (110). Primary candidal pneumonia is extremely rare. The main risk factors for serious candidal infections in HSCT recipients are advanced age, unmatched donor, neutropenia, acute GVHD, underlying disease, corticosteroid therapy, and duration of candidemia (112-114). Other risk factors for candidal infections are related to critical illness, including immunosuppressive therapy, neutropenia, multiple broad-spectrum antibiotics, total parenteral nutrition, and indwelling catheters. Candida albicans is the main species isolated; however, more resistant species are being increasingly isolated, including Candida glabrata, Candida krusei, and Candida parapsilosis (115) . The treatment of candidemia and deep infection is primarily fluconazole; however, if there is evidence of endophthalmitis or resistant organisms, then caspofungin is the treatment of choice (116) . Lipid formulation amphotericin B is another effective agent (117) .
Aspergillus is a leading cause of severe fungal infection following HSCT. The prevalence of IPA has been rising and currently ranges between 2% and 26% (118 -122) . The mortality rate of IPA is very high (74 -92%) (62, 120, 123) . Early diagnosis and effective antifungal therapy has resulted in a decrease in the mortality associated with the infection (124) . The onset of IPA has a bimodal distribution, with an early peak during the neutropenic phase and a late phase during the treatment of chronic GVHD (125) . The prevalence of IPA during the first peak is declining due to improvement in transplantation techniques and the use of granulocyte colony-stimulating factor that shorten the duration of neutropenia (122) . On the other hand, the prevalence in the second phase is rising with more aggressive therapy for chronic GVHD (120, 122) . The lung is the primary site of Aspergillus infection, leading to severe pneumonia with vascular invasion, necrosis, and hemorrhage. IPA disseminates to other organs, especially the brain, kidney, liver, and skin. In the lungs, the presentation is nonspecific, and fever may be absent. Pleuritic chest pain and hemoptysis, though nonspecific, should alert physicians to the possibility of IPA. Radiologically, IPA findings are nonspecific, including single or multiple nodules that may cavitate or focal or diffuse infiltrates (99). High-resolution computerized tomography of the chest should be performed early in the evaluation of patients suspected of having IPA. The routine early use of high-resolution computerized tomography in these patients has been shown to lead to earlier diagnosis and improved outcome (124) . Two radiologic signs that are highly suggestive, but not pathognomonic, of IPA on highresolution computerized tomography of the chest are the Halo sign and aircrescent sign. These signs are demonstrated in 33-60% of patients with proven IPA (99). Sputum cultures and BAL are positive in 45-62% of patients with IPA (126) . Isolation of Aspergillus species from sputum or BAL fluid has a high predictive value of 82% for IPA in this patient population (127) , although these tests are negative in 70% of patients with proven IPA (128) . Consequently, a positive sputum or BAL for Aspergillus should warrant therapy in the appropriate clinical and radiologic circumstances, whereas a negative study does not rule out IPA, and either further studies or empirical therapy should be considered. Surgical lung biopsy, either by video assisted thoracoscopy or thoracotomy, is the best diagnostic study available to confirm the diagnosis of IPA and is relatively well tolerated. Recent studies, which included HSCT recipients, showed that IPA is the most common diagnosis obtained by surgical lung biopsy and that the complications rate is Ͻ13% (129). Noninvasive methods to diagnose IPA have been recently introduced. These methods detect galactomannan, which is a component of the Aspergillus cell membrane, by either enzyme-linked immunosorbent assay or polymerase chain reaction from serum or BAL fluid. The serum enzymelinked immunosorbent assay for galactomannan is clinically available and has sensitivity of 98%; however, the specificity is Ͻ90% (122, 130, 131) . Studies indicate that a positive test may precede the radiologic features of IPA in 68% of patients and a definite diagnosis of IPA by 17 days (132) (133) (134) . However, given the low specificity of the test, the manufacturers of the assay recommend more than one positive sample to indicate a true positive test (110). Further studies are necessary to define the role of galactomannan antigen in the diagnosis of IPA. Therapy of IPA has been difficult, with low response rate and significant side effects. Recent advances in antifungal therapy introduced several new agents that are highly effective and well tolerated. Currently, the treatment of choice for patients with IPA is voriconazole, and in the case of breakthrough therapy, caspofungin is an alternative (133, 135) . The partial and complete response rate using these agents reaches 53% (135) . Another effective agent is lipid formulation amphotericin B (117) . In the case of voriconazole, it is essential to monitor liver function tests and the many drug interactions that may occur. The use of combination therapy in the management of severe, refractory IPA is currently under evaluation. Surgical treatment has a limited role in the management of patients with IPA and should only be considered in localized disease not responding to medical therapy or in cases of massive hemoptysis (136, 137) . There is no effective prophylactic therapy against IPA. Measures that decrease the risk of IPA in HSCT recipients include the use of HEPA filters, laminar air flow systems, and avoidance of admission to areas of the hospital where there is construction (138) . Several antifungal agents have been considered for prophylaxis; however, there are no studies that show consistent effectiveness.
P. carinii Pneumonia. P. carinii pneumonia (PCP) is rarely seen following HSCT due to the effective prophylaxis using trimethoprim-sulfamethoxazole (139) . Currently, the prevalence of PCP in HSCT recipients is negligible (140) . However, in 5% of patients, trimethoprimsulfamethoxazole is not well tolerated, and PCP should be considered in HSCT patients presenting with severe pneumonia who are not receiving this treatment or who are receiving other less effective prophylactic agents (141). The main risk factors for PCP in this patient population are treatment with corticosteroids or immunosuppressive therapy. The clinical presentation of PCP in HSCT recipients is more severe and fulminant than in human immunodeficiency virus patients; however, response to therapy is good if instituted early. BAL is the procedure of choice for the diagnosis of PCP, with positive yield in Ͼ90% of cases (142).
Cardiac Complications
Cardiac complications following HSCT are reported to vary from 2% to 28% and are the cause of transfer to the ICU in 19% of patients (6, 143-145). The main cardiac complications seen in this patient population are congestive heart failure, pericardial effusion, and arrhythmias.
Congestive Heart Failure. Congestive heart failure leading to pulmonary edema is the main cardiac complication following HSCT that is encountered in the ICU setting. The presence of preexisting cardiac dysfunction, even if subclinical, is a significant risk factor for congestive heart failure following HSCT. Ejection fraction before transplantation that is Ͻ50% has been correlated with increased risk for cardiogenic pulmonary edema following HSCT (146, 147). Other factors that lead to congestive heart failure posttransplantation include fluid overload associated with the infusion of chemotherapy, the presence of acute renal failure, venoocclusive disease, severe sepsis, and anemia. High-dose chemotherapy used in the preparation for HSCT, such as cyclophosphamide, cytosine arabinoside, paclitaxel, etoposide, and cisplatin, may be associated with significant cardiac toxicity and congestive heart failure (144, 148). Another potential cause of acute cardiac toxicity following HSCT is the infusion of dimethyl sulfoxide, cryopreserved marrow that may lead to congestive heart failure, bradyarrhythmias, or even cardiac arrest (149). One study suggested that a pretransplantation electrocardiogram showing QTc-interval prolongation was predictive of acute heart failure following HSCT (147). There is no convincing evidence that total body irradiation increases the prevalence of cardiac toxicity following HSCT (150). In the case of cyclophosphamide, the cardiac toxicity is dose dependent-cardiac complications are rare for doses of Ͻ120 mg/kg (151). The cardiac complications develop 5-16 days after infusion, with depressed left ventricular function, diastolic dysfunction, electrocardiographic changes, and pericardial effusion (151, 152). Histologic evidence suggests that the cardiac toxicity due to high-dose cyclophosphamide is through direct toxicity of the agent to the endothelial cells of the coronary vessels leading to myocardial necrosis (153). Although most of the cardiac changes are reversible, mortality due to cardiac toxicity associated with high-dose cyclophosphamide following HSCT is Ͻ2% (145, 154, 155). The management of congestive heart failure following HSCT is similar to that of other patients; however, the main challenge is to differentiate between cardiogenic pulmonary edema and other causes of pulmonary edema that may have a similar presentation or may co-exist with congestive heart failure. Electrocardiography and echocardiography are usually helpful diagnostic tests; however, right heart catheterization may also be necessary. Fluid restriction, diuresis, and angiotensin converting enzyme inhibitors are the mainstay of treatment. Correction of electrolyte disturbances and hypoxemia is helpful. Inotropic agents, such as dobutamine, are sometime necessary.
Pericardial Effusion. Pericardial effusion following HSCT is rare and is usually related to cyclophosphamide toxicity, viral syndrome, chronic GVHD, or renal failure (156) . Rarely may it be due to bacterial infection (157) (mainly S. aureus) or aspergillosis (158, 159) . Echocardiography is the best study to diagnose and evaluate the clinical significance of pericardial effusion. When the pericardial effusion is associated with hemodynamic compromise, it should be drained by subxiphoid pericardiectomy that allows direct visualization, hemostasis, and obtaining a biopsy. In emergency situations, percutaneous pericardiocentesis could be done; however, it may be associated with bleeding complications, especially in the presence of thrombocytopenia.
Endocarditis. Endocarditis is infrequently reported following HSCT. In the largest review of endocarditis in HSCT recipients, the prevalence was 1.3% (157) . The clinical presentation of endocarditis following HSCT could be subtle, and only 25% of the cases are diagnosed ante mortem (157) . The main risk factors for endocarditis were indwelling central venous catheters, disruption of skin and mucosal barriers by high-dose chemotherapy and GVHD, and the administration of immunosuppressive therapy (157) . Left-sided cardiac valves, especially mitral valve, are most commonly involved by endocarditis. The usual organisms isolated are Gram-positive bacteria, including S. aureus and S. viridans; however, there is a high prevalence of fungal encarditis, including Aspergillus and Candida species (157, 160, 161) . In one third of patients, no organisms are isolated, consistent with the diagnosis of nonbacterial thrombotic endocarditis (162, 163) . The presence of endocarditis in HSCT recipients is associated with very high mortality, despite aggressive antimicrobial therapy (157) . However, this increased mortality is usually related to co-morbid illnesses rather than the endocarditis itself.
Cardiac Arrhythmias. Cardiac arrhythmias are occasionally seen in critically ill HSCT recipients. They are most commonly associated with electrolyte abnormalities, hypoxemia, sepsis, MOSF, and use of vasopressor agents. Bradyarrhythmias have been described with infusion of hematopoietic stem cells cryopreserved with dimethyl sulfoxide (149). Supraventricular tachyarrhythmias are reported in 4.1% of HSCT recipients and are more frequent following autologous transplantation (164) . The main risk factors for these arrhythmias are older age, underlying diagnosis of non-Hodgkins lymphoma, and the presence of preexisting cardiac condition (144, 164, 165) . The most common supraventricular arrhythmias are atrial fibrillation or flutter. These types of arrhythmias commonly develop in the first month following transplantation (median, 6 days) and usually convert to sinus rhythm within 3 days of their onset (164) . The presence of supraventricular tachyarrhythmias following HSCT is associated with prolonged hospitalization and increased mortality (164) 
Gastrointestinal Complications
Gastrointestinal (GI) problems are common following HSCT. They are frequently encountered in patients during their ICU stay. Severe GI complications present themselves as abdominal pain, diarrhea, or GI bleeding. In addition to the common causes of acute abdominal pain in critically ill patients such as peptic ulcer disease, pancreatitis, and acute cholecystitis, other conditions that are unique to HSCT recipients should be considered, including chemotherapyrelated abdominal pain, GVHD of the intestines, intestinal pseudoobstruction, intestinal perforation, intestinal infections, and hemorrhagic enteritis. It is essential that clinicians taking care of HSCT recipients are aware of the above conditions that may lead to abdominal pain so that they can manage them appropriately and avoid unnecessary surgical interventions that are associated with significant mortality and morbidity.
GHVD of the Intestine. GHVD of the intestine is associated with abdominal pain, nausea, vomiting, diarrhea, and bleeding. The abdominal pain may be associated with peritoneal signs (166 -168) . Commonly, there are other manifestations of acute GVHD such as hepatitis and skin rash. A computerized tomographic scan of the abdomen will show bowel wall edema. Endoscopic biopsy is diagnostic; however, it is rarely necessary unless there are no other features of the disease. GVHD of the intestine usually responds well to intensification of the immunosuppressive therapy (166, 168) .
Intestinal Pseudoobstruction. Intestinal pseudoobstruction is a common cause of abdominal pain following HSCT and is frequently seen during the course of these patients in the ICU. Pathogeneses include GVHD, sepsis, narcotics, electrolyte disturbances, and chemotherapeutic agents. Treatment is supportive and is directed toward treating the underlying cause. Neostigmine may be useful in the treatment of those patients with persistent pseudoobstruction (169, 170) 
are CMV ulcers, corticosteroids therapy, and GVHD (166) . The management of this condition is similar to that of nontransplant patients.
Acute Pancreatitis. Acute pancreatitis is reported to occur in 20% of HSCT recipients at autopsy (171); however, clinically significant disease is rare, and the prevalence is 3.5% (171) . The main causes of acute pancreatitis following HSCT are medication use (trimethoprimsulfamethoxazole, corticosteroids, cyclosporine A), infections (CMV and adenovirus), GVHD, and biliary sludge (171) (172) (173) . The management of severe pancreatitis is supportive and treating the underlying problem.
Enteritis. Enteritis is another significant GI problem following HSCT, with reported prevalence of 43% after allogeneic HSCT (174 -176) . It is usually mild and self-limiting; however, in a small percentage of patients, it may be severe, leading to dehydration, with hypotension and acute renal failure. The main causes of enteritis following HSCT are GVHD, bacterial infection, the most common of which is Clostridia difficile enteritis, and viral infections such as rotavirus, adenovirus, CMV, herpes simplex virus, and herpes zoster virus (174, 177, 178) . Typhlitis is a rare but severe clostridial infection that involves the cecum and ascending colon. It is mainly seen during the neutropenic phase following HSCT (177) . The management of severe enteritis following HSCT includes supportive measures and treatment of the underlying pathogenesis. In the case of severe diarrhea, patients may respond to octreotide, a somatostatin analog, which inhibits the secretory hormones (179) . Anti-diarrhea agents should be avoided because they may precipitate pseudoobstruction. Enteritis due to rotavirus responds to oral immunoglobulins (180) . Prognosis of enteritis following HSCT is generally favorable (174) .
Gastrointestinal Bleeding. GI bleeding following HSCT has been reported in 7-18% of those patients (181) (182) (183) . A unique feature of GI bleeding in this patient population is that it tends to be diffuse mucosal bleeding that may involve the small intestine. It is also worsened by thrombocytopenia. The most common cause of GI bleeding in allogeneic HSCT recipients is GVHD (up to
to deep mucosal ulcers and necrosis, which may be associated with severe bleeding. Peptic ulcer disease is a rare cause of upper GI bleeding early post HSCT (6 -10% of all cases) (37). GI bleeding is an indicator of poor outcome in critically ill HSCT recipients, although it is rarely the cause of death (18, 181) .
Hepatic Complications
Liver failure is another significant problem in critically ill HSCT recipients and is usually related to sepsis and MOSF. However, other conditions may lead to severe liver disease following HSCT, including veno-occlusive disease, acute GVHD, viral hepatitis, and medications.
Veno-occlusive Disease. Veno-occlusive disease (VOD) is reported in 20 -50% of patients following HSCT (185) (186) (187) (188) . VOD arises from thrombosis of small central hepatic venules due to endothelial cell damage by high-dose chemotherapy. VOD usually develops in the first 21 days following HSCT, and the earliest signs of the syndrome are weight gain and tender hepatomegaly, followed by jaundice. A decrease in bilirubin level is an early indicator of recovery (187, 189) . Protein C and antithrombin III are reduced in patients with moderate to severe VOD and usually decrease before the clinical onset of VOD (190) . The clinical course of VOD varies from mild, self-limiting liver dysfunction to a rapidly fatal disease associated with MOSF, including acute renal failure and acute respiratory failure requiring mechanical ventilation (187) . The acute respiratory failure is commonly due to fluid overload or aspiration. The main risk factors for VOD are patient age, elevation of transaminases before HSCT, the intensity of conditioning regimen, and prolonged fever (187) . VOD frequency is similar in autologous compared with allogeneic HSCT (185, 187) . The diagnosis of VOD is based on the clinical picture (the onset of hyperbilirubinemia, hepatomegaly, and weight gain or ascites in the first 30 days following HSCT). Doppler ultrasound of the hepatic blood vessels shows reversal or diminished portal blood flow (189) . Percutaneous liver biopsy carries a high risk of bleeding. Hepatic vein catheterization with measurement of the hepatic venous pressure gradient (Ͼ10 mm Hg) and transvenous liver biopsy confirms the diagnosis of VOD but is rarely performed in clinical practice (191, 192) . The management of VOD is supportive and is directed toward sodium and fluid restriction, diuresis, paracentesis in cases of tense ascites, and avoiding infection and hepatotoxic medications. Thrombolytic treatment is associated with a 30% response rate, but case fatality approaches 10% (193) . Heparin and antithrombin III have been used with variable results (194) . Oral ursodeoxycholic acid (ursodiol) is useful in lowering bilirubin levels and may prevent further hepatic injury caused by free radicals generated by bile acids (195, 196) . VOD is fatal in 25-50% of patients (186 -188, 196) .
Other causes of liver dysfunction following HSCT include acute GVHD, although fulminant liver failure is rare (189) . Viral hepatitis due to adenovirus, herpes simplex virus, and herpes zoster virus may lead to severe hepatitis with a rapid increase in liver enzymes (167, 197) . Acyclovir is effective in the treatment of these infections. CMV infection commonly leads to hepatitis, although rarely severe. Hepatitis B and C may progress, leading to liver failure when immunosuppressive therapy for GVHD is tapered (198, 199) . Fungal infection involving the liver is rare and is usually part of a multiple system infection. The most common fungal species that involve the liver are Candida and Aspergillus (200) . Many medications used following HSCT contribute to liver disease, although they are rarely the cause of severe liver disease. These medications include cyclosporine A, fluconazole, voriconazole, antithymocyte globulins, interleukin-2, and total parenteral nutrition. Avoiding hepatotoxic drugs, monitoring drug levels, and adjusting doses are essential to the proper management of HSCT recipients, especially if they have liver disease.
Renal Complications
Acute renal failure is a common and serious problem complicating HSCT. The reported prevalence of acute renal failure following HSCT varies between 9% and 53% (201) (202) (203) (204) . The presence of acute renal failure significantly affects the mortality of HSCT recipients (204, 205) . Between 5% and 33% of these patients require renal replacement therapy (201, 206, 207) . Mortality in those requiring hemodialysis is high, with ranges between 84% and 100% (6, 205, 206) .
Acute renal failure following HSCT most commonly develops in the setting of MOSF secondary to sepsis or other causes (which could happen anytime following transplantation) (201, 202) . There are, however, specific pathogeneses of acute renal failure that are unique to HSCT. These conditions tend to occur in a predictable timeline (Fig. 1) . Acute renal failure in the first week following HSCT is generally related to tumor lysis syndrome or infusion of marrow cells. In the first month following transplantation, acute renal failure is commonly associated with VOD. Acute renal failure after the first month of transplantation may be related to hemolytic uremic syndrome, hemorrhagic cystitis, or cyclosporine A toxicity.
Tumor Lysis Syndrome. Tumor lysis syndrome is due to the breakdown of tumor cells following radiochemotherapy. The syndrome is rarely seen following HSCT because the underlying malignancy is usually in remission or partial relapse at the time of transplantation, so the burden of tumor cells is rarely high. In addition, patients routinely receive effective prophylaxis against this syndrome. When tumor lysis syndrome develops, it usually occurs in the first few days following chemotherapy and is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and oliguric renal failure. This syndrome is usually reversible by adequate intravenous hydration and alkalinization of the urine. Allopurinol, hydration, alkalinization of urine, and oral phosphate binding antacids 1-2 days before chemotherapy are effective in preventing this syndrome.
Infusion of Stem Cells. Infusion of stem cells may result in acute renal failure due to hemolysis, which leads to hemoglobinuria and proximal acute tubular necrosis. The infusion of hematopoietic stem cells cryopreserved with dimethyl sulfoxide probably contributes to intravascular hemolysis (149, 208) . Factors that increase the risk of acute renal failure in this situation are hypovolemia and acidosis (208) . Adequate hydration and alkalinization of the urine with adequate urine output protects against this complication.
Hemorrhagic Cystitis. Hemorrhagic cystitis is another cause of acute renal failure in the first 2 wks following HSCT and results in obstructive uropathy due to blood clots that obstruct the ureters or urethra. Hemorrhagic cystitis develops in 25% of allogeneic HSCT recipients (209) . The condition is precipitated by cyclophosphamide metabolites, busulfan, or irradiation. Hemorrhagic cystitis may also develop later (median, 40 -80 days) following HSCT secondary to BK virus, adenovirus, or CMV infections (210 -214) . Hemorrhagic cystitis is prevented by intravenous hydration, diuresis, irrigation of the urinary bladder, and the use of mesna.
Veno-oclusive Disease. VOD is the most common cause of acute renal failure in the first 10 -21 days following HSCT (203) . VOD is associated with a hepatorenal syndrome characterized by sodium retention, weight gain, and edema and ascites. This is followed by azotemia. The renal impairment in this syndrome is due to renal vasoconstriction secondary to a variety of mediators released by the damaged hepatic endothelial cells. These mediators include endothelin, thromboxane A2, leukotrienes, platelet activating factor, and adenosine (186, 215) . The main risk factors for acute renal failure in patients with VOD are mismatched graft, age of Ͼ25 yrs, high baseline creatinine, sepsis, and the use of amphotericin B (186, 187, 215, 216) . Fifty percent of patients require renal replacement therapy, which is associated with poor prognosis (207, 217) . The degree of hyperbilirubinemia is a predictor for the need for hemodialysis. Pentoxifylline (tumor necrosis factor-␣ antagonist) has been used to prevent acute renal failure in patients with VOD; however, subsequent trials failed to show benefit from this treatment (218) .
Drug Nephrotoxicity. Drug nephrotoxicity is an important cause of acute renal failure and should be considered anytime following HSCT. Cyclosporine A causes intense afferent arteriolar vasoconstriction and nephrotoxicity, which is associated with hyperkalemia, metabolic acidosis, hyperuricemia, and hypomagnesemia (219) . Other drugs that lead to acute renal failure following HSCT include cytotoxic agents such as nitrosurea, methotrexate, and cyclophosphamide; antibiotics such as amphotericin B, acyclovir, foscarnet, and aminoglycosides; and immunosuppressive agents such as tacrolimus (219) . The combination of any of the above agents significantly increases the risk of acute renal failure. Preventing acute renal failure due to drugs involves minimizing the use of these agents, careful monitoring of drug levels, and maintaining adequate hydration and electrolytes balance.
Electrolytes Abnormalities. Electrolytes abnormalities are common following HSCT. These include hyponatremia, hypokalemia, and hypomagnesemia, and are related to intravenous fluids, diarrhea, total parenteral nutrition, renal insufficiency, and drugs such as diuretics, cyclophosphamide, amphotericin B, and cyclosporine A. Severe hyponatremia (serum Na, Ͻ125mEq/L) is reported in 19% of HSCT recipients a median of 19 days following transplantation (220) . The most common causes of severe hyponatremia are syndrome of inappropriate antidiuretic hormone, infections, diarrhea, GVHD, VOD, acute renal failure, and the effect of medications and intravenous fluids (220).
Neurologic Complications
The prevalence of clinically significant neurologic problems following HSCT is estimated to range between 11% and 18%, and these are generally more common following allogeneic transplantation (221, 222) . Based on an autopsy study, neurologic complications were the cause of death in 17% of HSCT recipients (223) . The risk factors for neurologic complications are high-dose chemotherapy, immunosuppressive therapy, GVHD, and thrombocytopenia (221) (222) (223) (224) (225) . Neurologic complications of HSCT are important causes of critical illness in this patient population, and they account for 6% of all admissions or transfers to the ICU (6).
Cerebrovascular Accident. Cerebrovascular accident (CVA) develops in approximately 3% of HSCT recipients and is slightly more common following allogeneic HSCT (5% vs. 1.2% in autologous HSCT) (225) . CVA develops a median of 28 days following HSCT (225) . The main causes of CVA are, in order, intracranial bleeding (predominately intracerebral and subarachnoid hemorrhage secondary to thrombocytopenia), cerebral infarction related to infection (predominantly due to aspergillosis), and noninfectious infarction due to thrombosis (225) . Nonbacterial thrombotic endocarditis is a rare cause of cerebral infarction seen in HSCT that is related to disseminated intravascular coagulation or hypercoagulable state (226) . The development of CVA is associated with poor outcome, and in a large study of CVA after HSCT the hospital mortality was 69.4% (225) . Age, oncologic diagnosis, type of HSCT, and time of CVA did not predict poor outcome. The management of CVA following HSCT is similar to that of nontransplantation patients. However, special attention should be made to correct thrombocytopenia and coagulopathy, and a careful evaluation should be made for an infectious pathogenesis. Surgical evaluation is necessary for prompt drainage of intracranial hematoma.
Central Nervous System Infections. Central nervous system infections account for 10% of neurologic complications following HSCT (221, 227) . The causes and time patterns of these infections are similar to that of other organs (Fig. 1) . The main causes of central nervous system infections are aspergillosis, which was found in 4.4% HSCT recipients who underwent post mortem examination (223) . Central nervous system involvement by aspergillosis is usually part of disseminated disease, with other evidence of the infection (224) . Prognosis of patients with central nervous system involvement is extremely poor (228) . Other causes of central nervous system infection in this patient population are CMV, herpes zoster virus, toxoplasma, Candida, Cryptococcus, and bacterial meningitis (227, 229, 230) .
Metabolic Encephalopathy. Metabolic encephalopathy is an important cause of neurologic symptoms in critically ill HSCT recipients. The prevalence of metabolic encephalopathy in HSCT recipients ranges between 3% and 13% and is more common following allogeneic transplantation (222, 223, 227) . The condition usually develops in the first 2 months following transplantation and usually presents with change in mental status or seizures (221) . Other patients may present with classic Wernicke encephalopathy, with altered mental status, ataxia, and ophthalmoplegia (231) . The main causes of metabolic encephalopathy following HSCT are hypoxemia, electro-lyte abnormalities, metabolic acidosis, sepsis, hepatic failure, and medications including sedatives and analgesics (223) . Thiamine deficiency, secondary to malabsorption associated with acute GVHD, has been suggested as the cause of Wernicke encephalopathy (222, 231) . Treatment of metabolic encephalopathy is supportive, including correction of electrolyte abnormalities and hypoxemia, withholding offending medications, and treatment of the underlying problems.
Treatment-Related Neurologic Complications. Treatment-related neurologic complications might lead to serious neurologic side effects. Cyclosporine A may lead to encephalopathy, leukoencephalopathy, generalized cerebellar dysfunction, hemiparesis, quadriplegia, and seizures (232, 233) . The risk of neurologic complications increases with history of cranial radiation, hypertension, uremia, hypomagnesemia, ␤-lactam antibiotics, and high-dose corticosteroids (224, 234) . OKT3 treatment has been associated with aseptic meningitis that may develop 24 -72 hrs after injection (235) . Pretreatment with corticosteroids may reduce or prevent this syndrome (236) . Antibiotics such as imipenem may be the cause of seizure activity. Corticosteroids are associated with myopathy, psychosis, and other problems resulting from withdrawal of this medication. Furthermore, the treatment of HSCT recipients in the ICU may lead to further neurologic complications, including critical care polyneuropathy and myopathy and prolonged effects of neuromuscular blocking agents and sedatives.
Acute GVHD. Acute GVHD is not specifically associated with neurologic complications, except for encephalopathy associated with other organ dysfunction. In contrast, chronic GVHD may be associated with polyneuropathy, polymyositis, and myasthenia gravis (232, 237, 238) . Most of these syndromes respond to intensifying immunosuppressive therapy (239) .
Hematologic Complications
HSCT is associated with several hematologic problems related to pancytopenia that lead to severe complications, including bleeding and infection. In this segment, we will concentrate on a specific complication related to HSCT, which is thrombotic thrombocytopenic purpura.
Thrombotic Thrombocytopenic Purpura. Thrombotic thrombocytopenic purpura (TTP) is one of the most severe hematologic complications related to HSCT. It is more commonly identified in allogeneic HSCT recipients (prevalence, 5-15% (240 -243)); however, TTP is also seen after autologous HSCT. The median time of onset of TTP is 44 days following HSCT (244) . The pentad of classic TTP is thrombocytopenia, microangiopathic hemolytic anemia, fever, neurologic signs, and renal impairment. Hemolytic uremic syndrome, which has also been described following HSCT, is similar to TTP but differs in the severity of renal impairment. The main risk factors for TTP following HSCT are older age, female sex, human leukocyte antigen mismatching, high-grade acute GVHD, cyclosporine treatment, and history of severe infection (240, 245, 246) . The proposed mechanisms of TTP following HSCT include endothelial damage due to chemotherapy or cyclosporine that led to release of cytokines, such as tumor necrosis factor-␣, that precipitate a prothrombotic state (247) . It is important to note that deficiency of von Willebrand factor-cleaving protein, which is implicated in the pathogenesis of classic TTP, does not play a role in TTP following HSCT (248) . There are other fundamental differences between TTP related to HSCT and idiopathic TTP. TTP following HSCT is sometimes difficult to diagnose because some of the diagnostic criteria are lacking (244) . For example, neurologic and renal signs are absent in 36% and 54% of HSCT recipients with TTP (243) . Furthermore, some of the diagnostic criteria may be part of other syndromes; for example, thrombocytopenia could be due to lack of engraftment, infection, or medications. Similarly, fever, neurologic problems, and renal problems are precipitated by many other conditions. So practically, the presence of thrombocytopenia and microangiopathic hemolytic anemia, without an alternative explanation, is sufficient to make the diagnosis of TTP following HSCT (243) . The most important differential diagnosis of TTP following HSCT is cyclosporine toxicity, which may lead to microangiopathic hemolytic anemia, renal impairment, and neurologic complications. There are even some reports that cyclosporine is one of the causes of TTP following HSCT (245, 246) . The management of TTP following HSCT includes discontinuing cyclosporine or tacrolimus and avoiding platelet transfusion. The role of plasma exchange, which is the mainstay of treatment in idiopathic TTP, is not clear (249 -251) (252)). The prognosis of TTP following HSCT is generally poor, and the mortality rate is around 70% (241, 242, 246, 248) . Mortality is higher if the syndrome develops in the first 120 days following HSCT, after treatment with cyclosporine or tacrolimus, or if there is neurologic deficit (243) . The only predictor of resolution of TTP is the absence of renal impairment (244) .
ICU Outcome
Admission of the HSCT recipient to the ICU carries a very high mortality. Early reports describe the mortality to be Ͼ90%, especially in those who require mechanical ventilation. During the past two decades, the prognosis for these patients has significantly improved ( Table  2 ). More recent reports show that ICU and hospital mortality rates are Ͻ33% and Ͻ56%, respectively (6, 253). Longterm survival, although improving, remains poor.
The improvement in survival is multifactorial and is probably related to the use of hematopoietic stem cells rather than bone marrow, nonmyeloablative regimens, shorter neutropenic phase, better antimicrobial prophylaxis, preemptive therapy of CMV infection, and improved antifungal therapy. In addition, improved intensive care, including lung protective ventilation strategies and the early use of noninvasive ventilation in these immunocompromised patients, have probably significantly contributed to the better ICU outcome (254, 255) . Furthermore, the multidisciplinary approach to the management of these patients, with a leading role played by intensivists, plays a significant role in the improved outcome of critically ill HSCT recipients.
Survival studies attempted to identify the variables that predict the outcome of critically ill HSCT recipients. A few studies have suggested that clinical characteristics before the admission to the ICU, such as age, type of HSCT, conditioning regimen, presence of neutropenia or GVHD, and time from transplantation to the admission to ICU, were important predictors of poor outcome. However, most of the studies have shown that these pre-ICU variables are not reliable and should not be used to determine suitability for transfer to the ICU. Furthermore, most studies show that measures of severity of illness such as the Acute Physiology and Chronic Health Evaluation (APACHE) II and Simplified Acute Physiology Score II have failed to predict the outcome of HSCT patients admitted to the ICU and consistently underestimate mortality in this patient population (5, 6). It is important to mention, however, that a recent study suggested that APACHE III was a reasonable prognostic tool in predicting hospital mortality in critically ill HSCT recipients (253) . Another recent study showed that high serum lactate level at admission to the ICU was a significant predictor of poor outcome (6). The outcome predictors that consistently predicted poor outcome of HSCT recipients admitted to the ICU were the need for mechanical ventilation and the presence of MOSF (Table 2 ). Acute respiratory failure requiring mechanical ventilation increased the odds of death in the ICU by 55.6 times (6). The presence of more than two organ system failures, regardless of the type of organ failure, significantly increased the mortality in this patient population (6). It is important to mention in this context that there are no absolute predictors of mortality. Only one study showed that all patients who had acute lung injury (FIO 2 of Ͼ0.6 or positive endexpiratory pressure of Ͼ5), hepatic and renal failure, and who required vasopressors for Ͼ4 hrs died (256) .
In addition to the improvement in ICU outcome reflected by recent reports studying HSCT recipients, there are few observations that warrant mentioning. The survival rate of HSCT recipients admitted to the ICU is similar to that of other critically ill patient populations, such as patients with sepsis or acute respiratory distress syndrome, and survival is directly related to the number of MOSF. This suggests that the outcome of HSCT recipients admitted to the ICU is more dependent on the underlying critical illness rather than the fact that they are transplant recipients. Consequently, these patients should be managed aggressively in a manner similar to that of other patient groups. However, it should be kept in mind that HSCT recipients are prone to unique infectious and noninfectious complications that warrant special consideration. Another observation is that the knowledge about the poor ICU outcome of HSCT recipients and the predictors of outcome mentioned above do not seem to change physicians' attitudes toward admitting these patients to the ICU and administering mechanical ventilation if necessary. The third observation is that long-term survival (Ͼ6 months) of HSCT recipients treated in the ICU remains poor; however, those who do achieve long-term survival (Ͼ6 months) tend to have normal organ function, and their prognosis is similar to that of those who did not require ICU admission (15).
In summary, HSCT is an important treatment for a wide variety of malignant and nonmalignant conditions. A significant number of patients who have had HSCT develop serious complications that involve almost any organ system and commonly lead to critical illness. Intensivists play a central role in the management of these critically ill patients. Although the mortality rate of critically ill HSCT recipients is high, survival is steadily improving. There are no definite predictors of survival in these patients; however, the presence of more than two organ system failures and the need for mechanical ventilation are especially associated with poor outcome. In general, critically ill HSCT recipients should be offered aggressive critical care therapy, including mechanical ventilation; however, these patients and their families should be counseled in advance about the outcome of such care. 
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